Gaps in the Care of Familial Hypercholesterolaemia in Australia: First Report From the National Registry.

2021-03

Pang, Jing

Sullivan, David R

Hare, David L

Colquhoun, David M

Bates, Timothy R

Ryan, Jacqueline D M

Bishop, Warrick

Burnett, John R

Bell, Damon A

Simons, Leon A

Mirzaee, Sam

Kostner, Karam M

Nestel, Paul J

Wilson, Andrew M

O'Brien, Richard C

Janus, Edward D

Clifton, Peter M

Ardill, Justin J

Chan, Dick C

van Bockxmeer, Frank

Watts, Gerald F

Cardiovascular disease

Familial hypercholesterolaemia

Lipids

Registry

Targets

Treatment

Journal Article

10.1016/j.hlc.2020.07.012

Familial hypercholesterolaemia (FH) is under-diagnosed and under-treated worldwide, including Australia. National registries play a key role in identifying patients with FH, understanding gaps in care and advancing the science of FH to improve care for these patients. The FH Australasia Network has established a national web-based registry to raise awareness of the condition, facilitate service planning and inform best practice and care services in Australia. We conducted a cross-sectional analysis of 1,528 FH adults enrolled in the registry from 28 lipid clinics. The mean age at enrolment was 53.4±15.1 years, 50.5% were male and 54.3% had undergone FH genetic testing, of which 61.8% had a pathogenic FH-causing gene variant. Only 14.0% of the cohort were family members identified through cascade testing. Coronary artery disease (CAD) was reported in 28.0% of patients (age of onset 49.0±10.5 years) and 64.9% had at least one modifiable cardiovascular risk factor. The mean untreated LDL-cholesterol was 7.4±2.5 mmol/L. 80.8% of patients were on lipid-lowering therapy with a mean treated LDL-cholesterol of 3.3±1.7 mmol/L. Among patients receiving lipid-lowering therapies, 25.6% achieved an LDL-cholesterol target of <2.5 mmol/L without CAD or <1.8 mmol/L with CAD. Patients in the national FH registry are detected later in life, have a high burden of CAD and risk factors, and do not achieve guideline-recommended LDL-cholesterol targets. Genetic and cascade testing are under-utilised. These deficiencies in care need to be addressed as a public health priority.

link

Heart, Lung & Circulation 2021; 30(3): 372-379

Heart, Lung & Circulation